CVS HEALTH Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CVS in the last 30 days.
See all $CVS insider activity →CVS Health agreed to a $20.5M settlement over data privacy allegations. The company is also working with improved full-year guidance and stronger cash generation. Investors are evaluating how the settlement and operational execution impact CVS Health's integrated model and financial outlook, with projections of $458.7B revenue and $11.3B earnings by 2029.
CVS agreed to a $20.5M settlement for a class action lawsuit alleging it shared customer data with an ad company. Affected customers can claim $5 or $10, with proof required for the higher amount. The deadline to file is Nov. 16, and payments can be received via PayPal, Venmo, or Zelle. A final approval hearing is set for Dec. 1.
CVS Health (CVS) and Criteo agreed to a $20.5M settlement over allegations of sharing user data without consent. The case involved CVS website tracking tools and targeted advertising. CVS, a $114B healthcare group, faces scrutiny on data handling across its operations. The settlement is small relative to CVS's revenue but may impact compliance costs and digital marketing practices.
Over the past 7 days, AlphAI's AI scored 24 news stories mentioning CVS (CVS HEALTH Corp). Coverage has skewed bearish: 3 bullish, 6 neutral, and 15 bearish.
Recent CVS coverage spans regulation, corporate actions and market movers.
The modest settlement cost is unlikely to materially affect CVS's earnings, but it may cause slight short‑term pressure as investors price in the compliance risk.
Settlement may cause modest downside as investors price in the liability.
The settlement introduces a modest compliance cost and potential restrictions on digital marketing tools.
The settlement introduces a modest liability and may prompt investors to reassess CVS's privacy risk exposure.
PBM involvement may affect CVS earnings outlook.
AlphAI scores every news story that mentions CVS with an AI model for sentiment and relevance, and aggregates insider trades from CVS HEALTH Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CVS Health agreed to a $20.5M settlement over data privacy allegations. The company is also working with improved full-year guidance and stronger cash generation. Investors are evaluating how the settlement and operational execution impact CVS Health's integrated model and financial outlook, with projections of $458.7B revenue and $11.3B earnings by 2029.
4 min readCVS agreed to a $20.5M settlement for a class action lawsuit alleging it shared customer data with an ad company. Affected customers can claim $5 or $10, with proof required for the higher amount. The deadline to file is Nov. 16, and payments can be received via PayPal, Venmo, or Zelle. A final approval hearing is set for Dec. 1.
1 min readCVS Health (CVS) and Criteo agreed to a $20.5M settlement over allegations of sharing user data without consent. The case involved CVS website tracking tools and targeted advertising. CVS, a $114B healthcare group, faces scrutiny on data handling across its operations. The settlement is small relative to CVS's revenue but may impact compliance costs and digital marketing practices.
3 min readCVS and Criteo agreed to a settlement over a lawsuit alleging illegal sharing of user data. Eligible customers may receive up to $10 with proof or $5 without. CVS denies wrongdoing. The settlement awaits court approval. Claims must be filed by Nov. 16, 2026.
2 min readFlorida sued Eli Lilly, Novo Nordisk, Sanofi, and pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx, alleging they inflated insulin prices. The state claims the companies raised list prices and exchanged rebates for preferred coverage, impacting patients paying based on list prices. The lawsuit seeks damages and injunctions, with no immediate price changes expected. Similar cases are ongoing nationwide.
3 min readCVS Health stock rose 3.2% to $87.76 after eight consecutive sessions of losses. The rally follows strong Q2 2026 results, with adjusted EPS up 40% YoY to $2.58 and revenue exceeding $106 billion. Management raised full-year EPS guidance to $7.90-$8.10 and increased cash flow outlook to $11.5 billion. UBS maintained a Buy rating with a $118 price target. Broader market gains and sector-wide buying interest also supported the rally.
2 min readCVS customers in Arizona may receive money from a lawsuit settlement. The company is involved in the case, and details are provided for claiming potential funds.
1 min readCVS customers who accessed its website or app before July 27 may qualify for a payment from a class-action settlement. The lawsuit alleges CVS shared user data with Criteo, which both companies deny. Customers can claim up to $10 by November 16, 2026, pending court approval.
2 min readCVS Health's Aetna unit expects $5.03B-$5.37B in adjusted operating income by 2026, returning to 2021 levels after a 2024 drop. A BCBSA study found AI tools added $1B in billable diagnoses without increased treatment, potentially impacting insurers like Aetna. CVS has not addressed this in its AI cost-cutting discussions. Analysts expect CVS's 2027 EPS to be $8.53, slightly above management's $8.44 estimate.
2 min readCVS Health shares declined 1.3% to $84.76 on Thursday, marking eight consecutive sessions of losses. The stock has fallen 9% in the past month but is up 7.8% year-to-date. A Texas bankruptcy judge approved a wind-down plan for CVS subsidiary Omnicare, which sold its business for $250M and settled a billing case for $440M. Analysts cite healthcare cost risks and regulatory changes as concerns.
1 min read
